ADPT
Adaptive Biotechnologies Corp
+1.03 (+3.72%)28.70USD1.5M成交股數4.6B市值–本益比(近四季)14.9股價營收比+21.5%營收年增(近四季)2026-11-04下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 71.6M+22% | 70.9M+35% | 71.7M+54% | 94.0M+118% | 58.9M+41% | 52.4M+15% | 46.4M+22% | 43.2M-12% | 41.9M | 45.8M | 37.9M | 48.9M |
| 營業成本 | 20.2M | 18.7M | 18.2M | 18.2M | 18.0M | 17.0M | 16.7M | 19.3M | 18.1M | 19.6M | 19.3M | 17.9M |
| 毛利 | 51.4M+26% | 52.2M+47% | 53.5M+80% | 75.8M+218% | 40.9M+72% | 35.5M+36% | 29.8M+60% | 23.9M-23% | 23.8M | 26.2M | 18.6M | 31.0M |
| 毛利率 | 71.8% | 73.6% | 74.6% | 80.7% | 69.4% | 67.6% | 64.1% | 55.3% | 56.9% | 57.2% | 49.0% | 63.4% |
| 研發費用 | 19.2M | 23.6M | 21.8M | 23.7M | 24.1M | 24.2M | 24.2M | 25.4M | 30.2M | 28.7M | 28.5M | 32.2M |
| 銷售管理費用 | 21.2M | 21.0M | 19.6M | 18.0M | 17.8M | 17.4M | 17.3M | 17.9M | 19.6M | 20.7M | 20.1M | 22.3M |
| 營業利益 | −15.8M-37% | −19.2M-35% | −12.8M-61% | 10.3M-122% | −25.0M-49% | −29.6M-58% | −32.6M-36% | −47.3M-1% | −48.8M | −71.1M | −51.0M | −47.8M |
| 營業利益率 | -22.0% | -27.1% | -17.8% | 10.9% | -42.5% | -56.4% | -70.3% | -109.6% | -116.5% | -155.2% | -134.4% | -97.7% |
| 稅後淨利 | −39.8M+55% | −20.0M-33% | −13.6M-58% | 9.5M-121% | −25.6M-46% | −29.9M-57% | −32.1M-36% | −46.2M-3% | −47.5M | −69.4M | −50.3M | −47.8M |
| 淨利率 | -55.6% | -28.3% | -18.9% | 10.2% | -43.5% | -56.9% | -69.1% | -107.0% | -113.5% | -151.7% | -132.7% | -97.7% |
| 稀釋 EPS | -0.25+47% | -0.13-35% | -0.08-64% | 0.06-119% | -0.17-48% | -0.20-58% | -0.22-37% | -0.31-6% | -0.33 | -0.48 | -0.35 | -0.33 |
| 稀釋股數 | 160M | 156M | 152M | 163M | 152M | 149M | 148M | 147M | 146M | 144M | 145M | 144M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 170M | 77.6M | 70.5M | 55.0M | 43.2M | 50.6M | 38.1M | 59.8M | 71.2M | 65.1M | 88.7M | 109M |
| 應收帳款 | 49.5M | 48.3M | 50.4M | 44.8M | 44.3M | 43.6M | 40.8M | 35.6M | 42.0M | 38.0M | 31.2M | 31.5M |
| 存貨 | 10.5M | 11.2M | 9.8M | 9.9M | 8.4M | 8.7M | 12.0M | 13.2M | 13.3M | 14.4M | 19.5M | 19.0M |
| 總資產 | 641M | 506M | 513M | 491M | 497M | 511M | 559M | 585M | 620M | 661M | 718M | 765M |
| 有息負債 | 0.00 | 125M | 127M | 129M | 130M | 132M | 133M | 132M | 132M | 131M | 127M | – |
| 總負債 | 490M | 282M | 288M | 286M | 317M | 321M | 335M | 343M | 346M | 353M | 356M | 369M |
| 股東權益 | 143M | 216M | 219M | 204M | 180M | 190M | 224M | 242M | 275M | 308M | 362M | 396M |
| 負債比 | 76.5% | 55.7% | 56.1% | 58.4% | 63.8% | 62.8% | 60.0% | 58.7% | 55.7% | 53.4% | 49.6% | 48.2% |
| 淨現金(現金 − 有息負債) | 170M | −47.2M | −56.1M | −74.4M | −87.3M | −80.9M | −94.6M | −72.3M | −60.3M | −65.6M | −38.0M | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −9.5M-67% | – | – | – | −28.5M | – | – | −38.4M | – | – | – |
| 資本支出 | – | 796K | – | – | – | 1.3M | – | – | 1.5M | – | – | – |
| 自由現金流 | – | −10.3M-65% | – | – | – | −29.7M | – | – | −39.9M | – | – | – |
| 折舊攤銷 | – | 3.4M | 3.7M | 4.0M | 4.1M | 4.3M | 4.2M | 4.6M | 5.2M | 2.8M | 5.8M | 5.7M |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | -14.6% | – | – | – | -56.7% | – | – | -95.2% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 277M
| Mrd Business | 212M | 76.7% | +45.9% |
|---|---|---|---|
| Immune Medicine Business | 64.6M | 23.3% | +93.4% |
產品／服務2025 年度 · 41.3M
| Immune Medicine Service Revenue | 41.3M | 100.0% | +205.9% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 277M | +54.8% | −59.5M | -21.5% | -0.39 | −48.9M |
| FY2024 | 179M | +5.1% | −159M | -89.1% | -1.08 | −98.9M |
| FY2023 | 170M | -8.1% | −225M | -132.3% | -1.56 | −167M |
| FY2022 | 185M | +20.1% | −200M | -108.0% | -1.40 | −200M |
| FY2021 | 154M | +56.9% | −207M | -134.3% | -1.48 | −254M |
| FY2020 | 98.4M | +15.6% | −146M | -148.6% | -1.11 | −168M |
| FY2019 | 85.1M | +52.8% | −68.6M | -80.6% | -1.01 | 194M |
| FY2018 | 55.7M | – | −46.4M | -83.4% | -3.67 | −38.6M |